The two papers
On 11 August 2026 the International Endodontic Journal published a perspective, “Animal Research in Pulp Biology: A Missing Link in the Translation of Regenerative Endodontics Innovations” (Kataoka, Noorani, Owaiwid, Ovik, Lin, Duncan, Lee, Sabatini; University at Buffalo and Dublin Dental University Hospital, Trinity College Dublin; DOI 10.1111/iej.70238, PMID 42581445). Eleven days later the Journal of Endodontics posted a narrative review, “Inflammation and Regeneration in the Dentine-Pulp Complex: Where Are We Now and Where Are We Going?” (Cooper, Friedlander, Hussaini, Ratnayake, Duncan; University of Otago and Trinity College Dublin; DOI 10.1016/j.joen.2026.08.019, PMID 42628720). Duncan is the shared co-author. Both full texts are paywalled; what follows is grounded in the published abstracts as indexed by PubMed and Europe PMC, plus the Crossref bibliographic records, and in this site’s own published record.
The argument both make
The perspective’s thesis, stated in its abstract: clinical translation of pulp biology, biomaterial, and tissue-engineering advances “remains limited or absent”, and the missing link is the lack of rigorously validated, clinically relevant preclinical models to carry in vitro findings through regulatory processes to human application. The authors acknowledge that novel alternative methodologies, meaning microfluidics, organoids, and organ-on-chip systems, are transforming early-stage screening and mechanistic work, but argue these cannot replicate the systemic elements animal models provide, namely immunity, vascularization, innervation, and aging, which regulators continue to require as whole-organism evidence before approving devices, drugs, or biologics. Their proposed frame is standardized orthotopic animal models of vital pulp treatment, and their stated obstacle is the absence of consensus on model selection and standardization. The review reaches the same structural point from the biology side: after summarizing decades of dentin-pulp inflammation and regeneration research, it concludes that high-quality preclinical in vitro, ex vivo, and animal models are essential to underpin evidence-based clinical translation. Neither paper reports new experimental data; both are argument and synthesis.
What the review adds on mechanism
The review’s summary of the preclinical literature is worth restating because it bounds the argument. As carious disease progresses, pulpal cells detect the shifting microflora and mount a cytokine-driven immune response in which neutrophils deploy their antimicrobial armamentarium, including neutrophil extracellular traps; the abstract calls this defensive response double-edged, damaging host tissue while fighting infection. Damaged-tissue signals combined with bacterial components activate pathways such as the inflammasome, and in people with type 2 diabetes the review notes that chronic inflammation can accelerate tissue aging and potentially increase pulpal mineralization events. Epigenetic and immunotherapeutic compounds have been shown, in this preclinical literature, to modulate inflammation and enable innate regenerative responses. Every one of those results is in vitro, ex vivo, or animal work; the review’s own conclusion is that the route from this mechanism catalog to a clinic runs through the standardized preclinical models the perspective says do not yet exist in consensus form.
Why this matters for the tracked programs
Every tier on this site’s ladder rests on exactly the evidence type these two papers say is underspecified. The anti-USAG-1 / TRG-035 program leans on ferret developmental work, including the imaging biomarker paper covered here on 2026-08-22; the bioengineered tooth germ program leans on mouse eruptions and a minipig scaffold study; the root-organoid program has nothing yet in an animal jaw. The pulp-dentin repair program sits one tier higher precisely because it has the narrow human exception, the 26-patient autologous pulp stem cell trial in immature incisors, and nothing beyond that space. The two August papers claim this pattern is not a coincidence but a pipeline gap: the field generates mechanisms and materials faster than it generates validated orthotopic models capable of converting either into a regulatory-grade efficacy claim.
Boundary, and the tension the perspective steps into
These are opinion and review articles, so treat them as a diagnosis by two senior groups, not as findings. One tension the perspective states rather than resolves: it argues for prioritizing animal models at a time when, as its own abstract notes, there is a global agenda to reduce and replace animal use in medical research. The authors’ case is that regulators still require whole-organism evidence. Both things are consistent with this site’s own record: the 2026-09-09 DPSC extracellular vesicle meta-analysis found the preclinical literature too heterogeneous in models, dosing, and readouts to yield an effect size, which is a symptom of the same missing standardization. The practical watch item is whether groups adopt common orthotopic vital pulp treatment protocols and reporting standards, since without that, no pooling of preclinical results, and therefore no credible translational estimate, becomes possible. The current field assessment at /field/ does not change on the strength of argument alone; no tier moves.
Provenance: grounded in the PubMed and Europe PMC records for both papers (PMID 42581445, PMID 42628720), the Crossref metadata for both DOIs, and this site’s ledger and program pages. Both full texts are paywalled and were not read. Method and sourcing standard at /method/.